Penn Researchers Receive $7.3 Million Grant Renewal from NCI to Study Esophageal Cancer

facebook twitter google print email
Media Contact:Karen Kreeger | | 215-349-5658August 1, 2014

Researchers at the Perelman School of Medicine at the University of Pennsylvania will receive $7.3 million over the next five years from the National Cancer Institute (NCI) to find new ways to treat esophageal cancer. This grant is a renewal of an NIH /NCI program funded over the last 10 years and is the only program of its kind funded by NCI for esophageal cancer.

“We are excited about this renewal, and it builds upon success in generating novel three-dimensional organ-like culture models, mouse models, and identifying key genes with clinical outcomes,” says Anil K. Rustgi, MD, the T. Grier Miller Professor of Medicine and Genetics and chief of the Gastroenterology Division, who is the overall principal investigator on the grant. “We have several candidate genes and pathways that serve as new and innovative targets for esophageal cancer, which we believe have implications in head and neck cancer as well as lung cancer.”

Continued research for esophageal cancer is critical for prolonging patient survival, especially since this type of cancer becomes prevalent in its later stages and patients often have a poor prognosis and reduced response to traditional chemoradiation therapy. Esophageal cancer is a common cancer worldwide and esophageal adenocarcinoma, one of two subtypes, has the fastest rate of increase of any cancer in the US. Rustgi presented to a Congressional Caucus in June 2014 on the Recalcitrant Cancer Research Act passed in 2013, of which esophageal cancer is one.

Three projects are the cornerstone of the grant:

Project One (Anil K. Rustgi, MD, Project Leader) will focus on the biological roles of the cooperation between p120-catenin and p53 tumor suppressor genes in the formation of esophageal tumor cells, as well as the interplay of these tumor cells with other proteins in the tumor microenvironment. 

Click here to view the full release.